BioLargo EBITDA per Employee
The EBITDA per Employee of BioLargo (BLGO) as of Jul 16, 2026 is -1.20 M USD. In the previous year, EBITDA per Employee was -481,222.22 USD — a change of 149.69% (lower).
Get this data via API
Financial Data API
EBITDA per Employee
-1.20 MUSD
YoY
149.69%
Last updated:
EBITDA per Employee of BioLargo is 2026 -1.20 M USD. EBITDA per Employee of BioLargo was 2025 -481,222.22 USD. It decreases by 149.69% lower compared to the previous year.
Access this data via the Eulerpool API
BioLargo Stock analysis
What does BioLargo do? BioLargo Inc is an American company that was originally founded in 1991 and is headquartered in Westminster, California. The company is active in various industries, including environment, health, and industry. BioLargo develops and markets innovative technologies and products for use in various areas. The company holds several patents worldwide and is known for its groundbreaking inventions and expertise.
Answer: BioLargo Inc is an American company that develops and markets innovative technologies and products for various industries, particularly in the areas of environment, health, and industry. The company is known for its groundbreaking inventions and holds several patents worldwide. BioLargo is one of the most popular companies on Eulerpool.
Frequently Asked Questions about BioLargo stock
EBITDA per Employee of BioLargo is -1.20 M USD in 2026.
Access this data via the Eulerpool API
Workforce — BioLargo
All Key Metrics — BioLargo
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth